Last 12 months
Inside the activity.
0 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2022 Filed Sep 2, 2022 21:27 UTC |
Sirard CynthiaChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097620 · tm2225099-9_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 21:28 UTC |
O'Mahony John MarkChief Manufacturing Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097621 · tm2225099-10_4seq1.xml · derivative · entry 1 O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:23 UTC |
LI WILLIAMDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097615 · tm2225099-3_4seq1.xml · derivative · entry 1 LI WILLIAM · CIK 0001273806 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:25 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec.
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097617 · tm2225099-6_4seq1.xml · derivative · entry 1 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:26 UTC |
LAWLOR AUGUSTINEChief Operating Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097619 · tm2225099-8_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 21:25 UTC |
Mirabelli ChristopherDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097618 · tm2225099-7_4seq1.xml · derivative · entry 1 Mirabelli Christopher · CIK 0001262326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was awarded pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:22 UTC |
LOSCALZO JOSEPHDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097614 · tm2225099-2_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:20 UTC |
Mashiach NissimDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097613 · tm2225099-1_4seq1.xml · derivative · entry 1 Mashiach Nissim · CIK 0001357777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:24 UTC |
Dietz Thomas JohnDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097616 · tm2225099-5_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:46 UTC |
Granfield ChristineVP, Head of Reg Affairs/Qual
|
GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011048 · tm225302-6_4seq1.xml · derivative · entry 1 Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:47 UTC |
Bertagnolli MonicaDirector
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011050 · tm225302-1_4seq1.xml · derivative · entry 1 Bertagnolli Monica · CIK 0001761030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:50 UTC |
Sirard CynthiaChief Medical Officer · 10% owner
|
GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011060 · tm225302-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:51 UTC |
O'Mahony John MarkChief Manufacturing Officer
|
GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011062 · tm225302-5_4seq1.xml · derivative · entry 1 O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:49 UTC |
LI WILLIAMDirector
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011054 · tm225302-10_4seq1.xml · derivative · entry 1 LI WILLIAM · CIK 0001273806 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:47 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner
|
GrantRestricted Stock Units · Derivative | 325,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011049 · tm225302-7_4seq1.xml · derivative · entry 1 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:49 UTC |
LAWLOR AUGUSTINEChief Operating Officer · 10% owner
|
GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011055 · tm225302-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:48 UTC |
Mirabelli ChristopherDirector · 10% owner · Chairman of the Board
|
GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011052 · tm225302-2_4seq1.xml · derivative · entry 1 Mirabelli Christopher · CIK 0001262326 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:50 UTC |
LOSCALZO JOSEPHDirector
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011059 · tm225302-11_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:50 UTC |
Mashiach NissimDirector
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011061 · tm225302-12_4seq1.xml · derivative · entry 1 Mashiach Nissim · CIK 0001357777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:48 UTC |
Dietz Thomas JohnDirector
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011051 · tm225302-8_4seq1.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 06:02 UTC |
CAVANAUGH JAMES HDirector
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001104659-22-011079 · tm225302-9_4seq1.xml · derivative · entry 1 CAVANAUGH JAMES H · CIK 0001013473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:21 UTC |
PERCEPTIVE ADVISORS LLC10% owner
EDELMAN JOSEPH10% owner
|
PurchaseWarrants (right to buy) · Derivative | 3,508,771 | $2.85 Strike: $0.00 | $9,996,488.58 |
DisclosureSEC source: 0001062993-21-008980 · form4.xml · derivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,508,771 Underlying: Common Stock · 3,508,771 shares Expires not disclosed F1 · derivative.exercise_date: The pre-funded warrants are immediately exercisable, provided that the warrants may not be exercised if the holder and its affiliates would beneficially own in excess of 4.99% of the Issuer's common stock outstanding after giving effect to the exercise. F1 · derivative.expiration_date: The pre-funded warrants are immediately exercisable, provided that the warrants may not be exercised if the holder and its affiliates would beneficially own in excess of 4.99% of the Issuer's common stock outstanding after giving effect to the exercise. F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 21:48 UTC |
BeOne Medicines Ltd.10% owner
|
PurchaseCommon Stock | 2,543,800 | $2.85 | $7,249,830.00 |
DisclosureSEC source: 0001651308-21-000197 · wf-form4_163286569005826.xml · nonDerivative · entry 1 BeiGene, Ltd. · CIK 0001651308 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,348,437 F1 · kind: On September 24, 2021, BeiGene, Ltd. purchased 2,543,800 shares of common stock of the Issuer for $2.85 per share pursuant to an underwritten public offering. Read SEC document |
| September 08, 2021 Filed Sep 11, 2021 01:01 UTC |
Bertagnolli MonicaDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,150 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001104659-21-114807 · tm2127401-1_4seq1.xml · derivative · entry 2 Bertagnolli Monica · CIK 0001761030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,150 Underlying: Common Stock · 16,150 shares Expires 2031-09-07 F2 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable with respect to 50% of the Option on September 30, 2021, and with respect to the remaining 50% of the Option on December 31, 2021. Read SEC document |
| September 08, 2021 Filed Sep 11, 2021 01:01 UTC |
Bertagnolli MonicaDirector
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001104659-21-114807 · tm2127401-1_4seq1.xml · derivative · entry 1 Bertagnolli Monica · CIK 0001761030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 8, 2021, the Vesting Start Date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:36 UTC |
Granfield ChristineVP, Head of Reg Affairs/Qual
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074449 · tm2117938-6_4seq1.xml · derivative · entry 1 Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:35 UTC |
Sirard CynthiaChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074447 · tm2117938-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:35 UTC |
O'Mahony John MarkChief Manufacturing Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074448 · tm2117938-5_4seq1.xml · derivative · entry 1 O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:32 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074445 · tm2117938d2_4seq1.xml · derivative · entry 1 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:33 UTC |
LAWLOR AUGUSTINEChief Operating Officer · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074446 · tm2117938-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:30 UTC |
Mirabelli ChristopherDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074444 · tm2117938-1_4seq1.xml · derivative · entry 1 Mirabelli Christopher · CIK 0001262326 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:58 UTC |
CAVANAUGH JAMES HDirector
|
OtherWarrant (Right to Buy) · Derivative | 1,154 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021032 · tm216410-3_4seq1.xml · derivative · entry 1 CAVANAUGH JAMES H · CIK 0001013473 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,154 Underlying: Common Stock, $0.001 par value per share · 1,154 shares Expires 2026-02-05 F1 · kind: These warrants to purchase common stock were acquired by the reporting person in connection with a transfer (the "Transfer"), for no consideration, of warrants to purchase common stock by HealthCare Ventures IX, L.P. ("HCVIX") to the limited partners of HCVIX, including the reporting person, on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P., the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F2 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F1 · ownership.direct: These warrants to purchase common stock were acquired by the reporting person in connection with a transfer (the "Transfer"), for no consideration, of warrants to purchase common stock by HealthCare Ventures IX, L.P. ("HCVIX") to the limited partners of HCVIX, including the reporting person, on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P., the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:57 UTC |
HealthCare Ventures IX, L.P.10% owner
Healthcare Partners IX, L.P.10% owner
Healthcare Partners IX, LLC10% owner
|
OtherWarrant (Right to Buy) · Derivative | 571,428 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021029 · tm216410-1_4seq1.xml · derivative · entry 1 HealthCare Ventures IX, L.P. · CIK 0001490245 · 10% owner Healthcare Partners IX, L.P. · CIK 0001697027 · 10% owner Healthcare Partners IX, LLC · CIK 0001698828 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 571,428 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F2 · kind: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. F3 · kind: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by the reporting persons on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by the reporting persons on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F2 · ownership.direct: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:58 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec.
|
OtherWarrant (Right to Buy) · Derivative | 11,544 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021031 · tm216410-2_4seq1.xml · derivative · entry 2 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,544 Underlying: Common Stock, $0.001 par value per share · 11,544 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F4 · kind: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F4 · ownership.direct: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:58 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec.
|
OtherWarrant (Right to Buy) · Derivative | 571,428 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021031 · tm216410-2_4seq1.xml · derivative · entry 1 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 571,428 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F2 · kind: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F2 · ownership.direct: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:58 UTC |
Mirabelli ChristopherDirector
|
OtherWarrant (Right to Buy) · Derivative | 11,544 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021030 · tm216410-4_4seq1.xml · derivative · entry 2 Mirabelli Christopher · CIK 0001262326 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,544 Underlying: Common Stock, $0.001 par value per share · 11,544 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F4 · kind: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F4 · ownership.direct: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:58 UTC |
Mirabelli ChristopherDirector
|
OtherWarrant (Right to Buy) · Derivative | 571,428 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021030 · tm216410-4_4seq1.xml · derivative · entry 1 Mirabelli Christopher · CIK 0001262326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 571,428 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F2 · kind: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F2 · ownership.direct: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 13:55 UTC |
LAWLOR AUGUSTINEChief Operating Officer · 10% owner
|
Tax withholdingWarrant (Right to Buy) · Derivative | 11,544 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021299 · tm216410-5_4seq1.xml · derivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,544 Underlying: Common Stock, $0.001 par value per share · 11,544 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F4 · ownership.nature: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 13:55 UTC |
LAWLOR AUGUSTINEChief Operating Officer · 10% owner
|
OtherWarrant (Right to Buy) · Derivative | 571,428 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021299 · tm216410-5_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 571,428 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F2 · kind: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F2 · ownership.nature: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:57 UTC |
Granfield ChristineVP, Head of Reg Affairs/Qual
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008998 · tm214605-6_4seq1.xml · derivative · entry 1 Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:56 UTC |
Sirard CynthiaChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008995 · tm214605-4_4seq1.xml · derivative · entry 2 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:56 UTC |
Sirard CynthiaChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008995 · tm214605-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:56 UTC |
O'Mahony John MarkChief Manufacturing Officer
|
GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008997 · tm214605-5_4seq1.xml · derivative · entry 2 O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:56 UTC |
O'Mahony John MarkChief Manufacturing Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008997 · tm214605-5_4seq1.xml · derivative · entry 1 O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 02:54 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner
|
GrantRestricted Stock Units · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008991 · tm214605-1_4seq1.xml · derivative · entry 2 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 02:54 UTC |
ONSI DOUGLAS EDirector · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008991 · tm214605-1_4seq1.xml · derivative · entry 1 ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec. · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 02:55 UTC |
LAWLOR AUGUSTINEChief Operating Officer · 10% owner
|
GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008992 · tm214605-3_4seq1.xml · derivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 02:55 UTC |
LAWLOR AUGUSTINEChief Operating Officer · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008992 · tm214605-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:58 UTC |
Mirabelli ChristopherDirector · 10% owner
|
GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008999 · tm214605-2_4seq1.xml · derivative · entry 2 Mirabelli Christopher · CIK 0001262326 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:58 UTC |
Mirabelli ChristopherDirector · 10% owner
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008999 · tm214605-2_4seq1.xml · derivative · entry 1 Mirabelli Christopher · CIK 0001262326 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.